乌尔索酸配方有效诱导亡和限制炎症在银病模型在体外
Ewa Bielecka1, Natalia Zubrzycka1,2,3, Karolina Marzec1,2
1Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387 Cracow, Poland.
Biomedicines
|April 27, 2024
概括
乌尔索酸 (UA) 通过减少炎症和皮肤细胞过度生长,在治疗牛皮方面表现有前途. 局部用BIGEL配方的UA显著提高了它的有效性,提供了一种新的治疗方法.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 牛皮是一种常见的炎症性皮肤疾病,具有具有挑战性的管理.
- 需要新的,具有成本效益和可访问的治疗方法.
- 乌尔索酸 (UA) 是一种三类,具有抗炎和促的特性.
研究的目的:
- 调查乌尔索酸 (UA) 在管理与牛皮相关的炎症和角质细胞过度增殖方面的潜力.
- 在皮病的体外模型中评估UA的疗效.
- 开发和评估UA的新型局部配方,以提高生物可用性.
主要方法:
- 使用皮肤和免疫细胞进行体外研究,以评估UA对牛皮相关炎症的影响.
- 评估UA对细胞因子 (IL-6,IL-8) 和牛皮生物标志物的产生 (S100A7,S100A8,S100A9) 的影响.
- 混合纳米乳液和双凝局部系统的开发,以提高UA的生物可用性和有效性.
主要成果:
- 乌尔索酸限制了IL-6和IL-8的产生,以应对炎症刺激.
- 氨酸降低了牛皮生物标志物S100A7,S100A8和S100A9.9的表达.
- 通过非炎症性亡诱导,UA缓解了角质细胞的过度增殖,而不会对免疫细胞产生负面影响.
- 与单独UA相比,UA的局部双凝配方在限制角质细胞反应方面表现出更高的疗效.
结论:
- 局部的乌尔索酸配方在体外表现出显著的抗炎活性.
- 氨酸有效地减少了牛皮炎炎症和过度增殖的关键标志物.
- 新的局部输送系统,特别是bi-gel,增强了UA在牛皮治疗中的治疗潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


